Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT02172989 Completed - Clinical trials for Benign Breast Neoplasm

Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Benign Breast Neoplasm.

Start date: June 2014
Phase: Phase 1/Phase 2
Study type: Observational [Patient Registry]

Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has been used for breast cancer surgery such as sentinel lymph node (SLN) mapping and breast cancer localization. In this study, our hypothesis are as following: 1. As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome. 2. indocyanine green (ICG) permitted accurate preoperative and intraoperative detection of the SLNs as well as nonpalpable benign brest lesion in patients with breast cancer.

NCT ID: NCT02171741 Completed - Neoplasms Clinical Trials

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Start date: April 2005
Phase: Phase 1
Study type: Interventional

Study to determine the maximum tolerated dose (MTD) for various treatment durations of BIBW 2992 when administered in combination with docetaxel as determined by drug-related adverse events (AEs) as well as Pharmacokinetics, overall safety and antitumor efficacy.

NCT ID: NCT02171728 Completed - Neoplasms Clinical Trials

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Start date: November 2004
Phase: Phase 1
Study type: Interventional

Investigation of maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992

NCT ID: NCT02171702 Completed - Neoplasms Clinical Trials

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours

Start date: November 2004
Phase: Phase 1
Study type: Interventional

The primary objective of the study was to identify the maximum tolerated dose and to evaluate safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992.

NCT ID: NCT02171676 Completed - Neoplasms Clinical Trials

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Start date: May 2005
Phase: Phase 1
Study type: Interventional

Maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic parameters, and efficacy of pulsatile administration of BIBW 2992 in combination with docetaxel (Taxotere®)

NCT ID: NCT02171663 Completed - Neoplasms Clinical Trials

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

Start date: March 2004
Phase: Phase 1
Study type: Interventional

The primary objective was the assessment of safety of BIBW 2992 as assessed by the maximum tolerated dose (MTD). Secondary objectives were collection of overall safety data, antitumor efficacy data, as well as the determination of pharmacokinetics and the pharmacodynamic modulation of biomarkers by BIBW 2992.

NCT ID: NCT02171650 Completed - Neoplasms Clinical Trials

BIBW 2992 in Patients With Advanced Solid Tumors

Start date: December 2004
Phase: Phase 1
Study type: Interventional

The primary objective was to collect safety data for BIBW 2992.

NCT ID: NCT02171637 Completed - Neoplasms Clinical Trials

Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Start date: November 2003
Phase: Phase 1
Study type: Interventional

Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2 (HER2) immunohistochemical status with objective tumour responses

NCT ID: NCT02170350 Terminated - Malignant Neoplasm Clinical Trials

Brief Mindful Meditation Practice in Improving Quality of Life in Patients With Cancer Undergoing Radiation Therapy

Start date: June 6, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well brief mindful mediation practice works in improving quality of life in patients with cancer undergoing radiation therapy. Brief mindful mediation practice may improve the well-being and quality of life of patients with cancer who are undergoing radiation therapy by increasing levels of mindfulness and reducing stress, anxiety/depression, and fatigue.

NCT ID: NCT02170168 Completed - Neoplasms Clinical Trials

The Orkdal Model. Collaboration Between Specialist and Community Care Within Palliative Cancer Care

Start date: November 2014
Phase:
Study type: Observational

The overall aim of this project is to deliver better health care services through improved coordination of cancer care within specialist care (at the local hospital Orkdal Hospital) and community care (13 municipalities in the Orkdal region, Norway), and between these two levels in the health care system. "The Orkdal model" is developed and will be implemented and evaluated within cancer care. Cancer patients living in one of the 12 municipalities participating in the formal collaboration "Samhandlingsenheten i Orkdalsregionen" (SIO), or the municipality of Oppdal, having metastatic and/or loco-regional disease will be included in the study. Carers and health care providers will be included as well. Results from this project will be transferable to other parts of Norway and/or to other countries as well as to patients with other diagnoses causing complex conditions, such as chronic heart-, lung- and neurological disease.